Marshall Posner, MD
Hematology-Oncology, Cancer (Oncology)
Dr. Posner is Professor of Medicine, Director of Head and Neck Medical Oncology, Associate Director of the Center for Personalized Cancer Therapeutics, and Co-Leader of the Cancer Clinical Investigation Program for The Tisch Cancer Institute. Dr. Posner has been engaged in clinical and translational research in cancers of the head and neck, HIV, and immunity for more than 40 years. He develops therapies to optimize treatment and advance early diagnosis and screening; he developed the TPF chemotherapy regimen for induction chemotherapy in head and neck cancer and curative rituximab therapy for Pemphigus Vulgaris. Dr. Posner’s current research is in the area of virally caused head and neck cancers. He is also investigating models that translate genetic findings into therapeutic treatment. Dr. Posner has served on numerous NCI study sections and review committees. He has authored over 250 peer reviewed clinical, laboratory and translational scientific publications covering cancer therapeutics, monoclonal antibodies and immunology, autoimmune disease, and infectious diseases.
Dr. Posner is on Twitter at @marshposnerMD
In the News:
Dr. Posner discusses HPV-related oral cancer in the New York Times.
Dr. Posner discusses the warning signs of oral cancer and what to watch out for on the Katie Couric show.
The ASCO Post features Dr. Posner discussing "Challenges, Progress, and Future Directions in Head and Neck Cancer" (March 1, 2012)
Dr. Marshall Posner discusses the link between HPV and oropharyngeal cancers in The Daily News feature The Daily Check Up.
- The Mount Sinai Hospital
AIDS/HIV, Anti-Tumor Therapy, Cellular Immunity, Immunology, Tumorigenesis, Viruses and Virology